Navigation Links
Free statins with fast food could neutralize heart risk, scientists say
Date:8/12/2010

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.

Statins reduce the amount of unhealthy "LDL" cholesterol in the blood. A wealth of trial data has proven them to be highly effective at lowering a person's heart attack risk.

In a paper published in the Sunday 15 August issue of the American Journal of Cardiology, Dr Darrel Francis and colleagues calculate that the reduction in cardiovascular risk offered by a statin is enough to offset the increase in heart attack risk from eating a cheeseburger and a milkshake.

Dr Francis, from the National Heart and Lung Institute at Imperial College London, who is the senior author of the study, said: "Statins don't cut out all of the unhealthy effects of burgers and fries. It's better to avoid fatty food altogether. But we've worked out that in terms of your likelihood of having a heart attack, taking a statin can reduce your risk to more or less the same degree as a fast food meal increases it."

One statin, simvastatin, is already available in low doses (10mg) over the counter at pharmacies without a prescription. Other statins are so far only prescribed by doctors, and limited by cost to patients at particular risk of heart attack or stroke. However, the cost of the tablets has fallen sharply in recent years (from ~40/month to ~1.50/month), such that the cost to the NHS of seeing a doctor is much greater than the cost of the tablet.

"It's ironic that people are free to take as many unhealthy condiments in fast food outlets as they like, but statins, which are beneficial to heart health, have to be prescribed," Dr Francis said.

Statins have among the best safety profiles of any medication. A very small proportion of regular statin users experience significant side effects, with problems in the liver and kidneys reported in between 1 in 1,000 and 1 in 10,000 people.

"Everybody knows that fast food is bad for you, but people continue to eat it because it tastes good. We're genetically programmed to prefer high-calorie foods, and sadly fast food chains will continue to sell unhealthy foods because it earns them a living.

"It makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments that are provided free of charge. It would cost less than 5p per customer not much different to a sachet of ketchup.

"When people engage in risky behaviours like driving or smoking, they're encouraged to take measures that minimise their risk, like wearing a seatbelt or choosing cigarettes with filters. Taking a statin is a rational way of lowering some of the risks of eating a fatty meal."

Studies have shown a clear link between total fat intake and blood cholesterol, which is strongly linked to heart disease. Recent evidence suggests that trans fats, which are found in high levels in fast food, are the component of the Western diet that is most dangerous in terms of heart disease risk.

Dr Francis and his colleagues used data from a previous large cohort study to quantify how a person's heart attack risk increases with their daily intake of total fat and trans fat. He compared this with the decrease in risk from various statins, based on a meta-analysis of seven randomised controlled trials.

The results showed that most statin regimes are able to compensate for the relative risk increase from eating a cheeseburger and a small milkshake.

The researchers note that studies should be conducted to assess the potential risks of allowing people to take statins freely, without medical supervision. They suggest that a warning on the packet should emphasise that no tablet can substitute for a healthy diet, and advise people to consult their doctor for more advice.


'/>"/>

Contact: Sam Wong
sam.wong@imperial.ac.uk
44-020-759-42198
Imperial College London
Source:Eurekalert

Related biology news :

1. Statins may treat blood vessel disorder that can lead to fatal strokes
2. Statins may prevent miscarriages
3. Deathstalker scorpion venom could improve gene therapy for brain cancer
4. Innovation could bring super-accurate sensors, crime forensics
5. UofL public health research could impact environmental policy decisions
6. New catalyst of platinum nanoparticles could lead to conk-out free, stable fuel cells
7. New lab test could identify imatinib resistance
8. Kids could get more whole grains from after-school snacks, University of Minnesota study finds
9. Waterborne diseases could cost over $500 million annually in US
10. Steam process could remove CO2 to regenerate amine capture materials
11. Engineering could give reconstructive surgery a facelift
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... Research and Markets has announced the addition ... report to their offering. ... The global ... from USD 6.21 Billion in 2016, growing at a CAGR of ... bioinformatics market is driven by the growing demand for nucleic acid ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... CALGARY , Dec. 5, 2016 /PRNewswire/ - ... announced  that the independent Data and Safety Monitoring ... trial in high-risk cardiovascular disease (CVD) patients has ... that the study should continue as planned without ... and noted that no safety or efficacy concerns ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Eisai ... 3 open-label two-year study of rufinamide, which were ... American Epilepsy Society (AES) held from December 2-6 ... of final two-year safety, tolerability and cognitive data ... rufinamide experienced similar safety and tolerability profiles, cognitive ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... A microbiome impact grant award has been made to Dr. Renato Polimanti of ... and drinking on the oral microbiome. Grant proposals have been vetted by the ...
Breaking Biology Technology: